- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
– Industry veteran strengthens Pyxis team with expertise in clinical development, medical affairs and antibody-drug conjugates (ADCs) – CAMBRIDGE, Mass., Sept. 14, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the appointment of Jay M. Feingold, M.D., Ph.D., as Chief Medical Officer. “Jay’s track record of success taking oncology ADC programs from discovery […]
–  Seasoned industry executives add significant operating experience to Pyxis’ Board of Directors – CAMBRIDGE, Mass., Sept. 7, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the appointments of Freda Lewis-Hall, M.D., Thomas Civik, Darren Cline, and Mark Chin to its Board of Directors. These strategic appointments strengthen the company’s operational, clinical, and […]
– Veteran biotech executive adds financial and operational expertise to growing Pyxis team – CAMBRIDGE, Mass., August 31, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the recent appointment of Pamela Yanchik Connealy, M.B.A., as its Chief Financial Officer.  Ms. Connealy will be leading the Finance, Investor Relations and Human Resources functions at […]
– Steve Monks, Ph.D., appointed as Chief Technical Officer, brings 20+ years in drug development and CMC, Quality, and Regulatory operations –– Ritu Shah, PMP, appointed as Chief Operating Officer, brings 20+ years of industry experience specializing in portfolio management and strategic planning –– Christoph Rader, Ph.D., and Anthony W. Tolcher, M.D., join Scientific Advisory […]